Peregrine Pharmaceuticals reported $6.38M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agenus AGEN:US USD 18.1M 809K
Amgen AMGN:US USD 1.29B 40M
AstraZeneca AZN:LN USD 3.35B 280M
Biocryst Pharmaceuticals BCRX:US USD 36.92M 1.1M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Celldex Therapeutics CLDX:US USD 6.53M 623K
Eli Lilly And LLY:US USD 1.61B 10.9M
GlaxoSmithKline GSK:LN GBP 1.97B 13M
Immunogen IMGN:US USD 33.62M 9.83M
Intrexon XON:US USD 10.14M 2.53M
Karyopharm Therapeutics KPTI:US USD 34.64M 2.69M
Macrogenics MGNX:US USD 15.35M 1.69M
Mannkind MNKD:US USD 22.64M 3.4M
Merk MRK:US USD 2.47B 13M
Minerva Neurosciences NERV:US USD 2.84M 6.57K
Newlink Genetics NLNK:US USD 3.92M 236K
Novartis NOVN:VX USD 3.4B 185M
Novavax NVAX:US USD 122.88M 14.72M
Peregrine Pharmaceuticals PPHM:US USD 6.38M 467K
Repligen RGEN:US USD 53.64M 1.01M
Xencor XNCR:US USD 12.37M 1.28M